Surrozen, Inc./DE

Churchill Capital Corp VII (Nasdaq: CHFW), sponsored by Churchill Capital — the blank-check franchise associated with financier Michael Klein — completed its initial public offering in 2022 with a focus on the healthcare and life sciences sector. The SPAC filed an 8-K with the SEC on May 15, 2025, under the combined name Surrozen, Inc./DE, the Delaware-incorporated clinical-stage biopharmaceutical company developing Wnt signaling pathway therapeutics for tissue repair and regeneration. The filing reflects active corporate development as the vehicle's business combination with Surrozen advances through its lifecycle. For complete filing history, deal timelines, and SPAC-level analytics on CHFW, sign up for full data access at SpacDesk.